NEW YORK (GenomeWeb) – Canaccord and William Blair have upgraded their ratings on Quidel’s shares to Buy and Outperform, respectively, based on its acquisition of Alere's Triage B-type natriuretic peptide assay and cardiovascular and toxicology diagnostic assets, announced yesterday.

Quidel agreed to pay $400 million for the assets and $40 million in contingent consideration. It expects the deal to close by Sept. 20.